<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04227041</url>
  </required_header>
  <id_info>
    <org_study_id>QingdaoZHT</org_study_id>
    <nct_id>NCT04227041</nct_id>
  </id_info>
  <brief_title>A Study of Pyrotinib Combined With Capecitabine for Metastatic HER-2 Positive Colorectal Cancer</brief_title>
  <official_title>Single-arm, Prospective, Open-label, Exploratory Study of Pyrotinib Combined With Capecitabine for Metastatic HER-2 Positive Colorectal Cancer Patients After at Least Second-line Standard Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qingdao Zhixin Health Technology Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Affiliated Hospital of Qingdao University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Qingdao Zhixin Health Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of pyrotinib combined with capecitabine in patients with
      metastatic her-2 positive colorectal cancer after standard treatment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 10, 2020</start_date>
  <completion_date type="Anticipated">January 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 10, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximally Tolerated Dose (MTD)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Evaluation of tumor burden based on RECIST criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Evaluation of tumor burden based on RECIST criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Evaluation of tumor burden based on RECIST criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration Of Response (DOR)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Evaluation of tumor burden based on RECIST criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Evaluation of tumor burden based on RECIST criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety]</measure>
    <time_frame>up to 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>HER-2 Positive Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>HER2 positive metastatic colorectal cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrotinib in combination with capecitabine</intervention_name>
    <description>Pyrotinib in combination with capecitabine</description>
    <arm_group_label>HER2 positive metastatic colorectal cancer</arm_group_label>
    <other_name>Capecitabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients should be histologically diagnosed with metastatic CRC and after receiving at
             least two standard treatment regimens；

          2. Patients with HER2 positive；

          3. Metastatic colorectal cancer (stage Ⅳ, T1-4N0-2M1)；

          4. Life expectancy is at least 6 months

          5. ECOG score 0-1；

          6. The functional level of the major organs must meet the following requirements (no
             blood transfusion within 2 weeks prior to screening, no use of leukocytes or
             platelets)：

        Exclusion Criteria:

          1. The histopathological type is mucinous adenocarcinoma or ovarian implant metastasis；

          2. Patients who have previously been treated with anti-Her2-targeted drugs；

          3. Patients with surgical opportunity or potential for surgical treatment；

          4. Patients with a high risk of bleeding or perforation due to a tumor that has
             apparently invaded adjacent organs (including large vessels) of the colorectal lesion
             or who have developed fistulas；

          5. Patients with any severe and/or uncontrolled disease;

          6. Patients with any or present brain metastases；

          7. Women who were pregnant or breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tao Jiang, Dr.</last_name>
    <phone>18661806663</phone>
    <email>jiangtao111@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Qingdao University Hospital</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 10, 2020</study_first_submitted>
  <study_first_submitted_qc>January 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>January 12, 2020</last_update_submitted>
  <last_update_submitted_qc>January 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Affiliated Hospital of Qingdao University</investigator_affiliation>
    <investigator_full_name>Nailong Yang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

